drugset / Trial / NCT04470752
Capsaicin for Post-stroke Dysphagia
Phase 2
Unknown
82 enrolled
Georg Kägi, MD
Cantonal Hospital of Aarau, Switzerland · collabUniversity Hospital, Basel, Switzerland · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Randomised, double blind, Phase 2 Trial to evaluate the efficacy of oral Capsaicin in patients with post-stroke dysphagia in the (sub-)acute setting.
Timeline
- Start
- 2021-08-24
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Capsaicin | Small molecule | 1 ug/ml | Oral |
Indications
No indication recorded.